HIV protease inhibitors saquinavir and nelfinavir are potent inhibitors of cathepsin L activity: A potential treatment for COVID-19 patients
| العنوان: | HIV protease inhibitors saquinavir and nelfinavir are potent inhibitors of cathepsin L activity: A potential treatment for COVID-19 patients |
|---|---|
| المؤلفون: | Yousef Al-Abed, Kevin J. Tracey, Mingzhu He, Timothy R. Billiar, Marcelo F. Montenegro |
| بيانات النشر: | Research Square Platform LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Nelfinavir, Coronavirus disease 2019 (COVID-19), Chemistry, Cathepsin L activity, viruses, medicine, HIV Protease Inhibitor, Pharmacology, Saquinavir, medicine.drug |
| الوصف: | The 2019 coronavirus disease pandemic (COVID-19) has mobilized efforts worldwide, and several ongoing clinical trials aimed at developing a drug-based treatment for its control. Cathepsin L is an endosomal cysteine protease that mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells and viruses/host cell endosome membrane fusion. Therefore, cathepsin L is a potential target for the treatment of COVID-19 patients. In this report, we describe a previously unknown inhibitory effect of two FDA-approved drugs, saquinavir and nelfinavir, on human cathepsin L activity. Whether the pivotal role for cathepsin L in Sars-Cov-2 infection described in vitro can be translated to humans, our results support immediate clinical trials of saquinavir or nelfinavir as a potential treatment for COVID-19 patients. |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::977c35bda94d332867bad62843db88a7Test https://doi.org/10.21203/rs.3.rs-37258/v1Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........977c35bda94d332867bad62843db88a7 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi...........977c35bda94d332867bad62843db88a7 845 3 unknown 844.685668945313 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........977c35bda94d332867bad62843db88a7&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => HIV protease inhibitors saquinavir and nelfinavir are potent inhibitors of cathepsin L activity: A potential treatment for COVID-19 patients
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Yousef+Al-Abed%22">Yousef Al-Abed</searchLink><br /><searchLink fieldCode="AR" term="%22Kevin+J%2E+Tracey%22">Kevin J. Tracey</searchLink><br /><searchLink fieldCode="AR" term="%22Mingzhu+He%22">Mingzhu He</searchLink><br /><searchLink fieldCode="AR" term="%22Timothy+R%2E+Billiar%22">Timothy R. Billiar</searchLink><br /><searchLink fieldCode="AR" term="%22Marcelo+F%2E+Montenegro%22">Marcelo F. Montenegro</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Research Square Platform LLC, 2020. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Nelfinavir%22">Nelfinavir</searchLink><br /><searchLink fieldCode="DE" term="%22Coronavirus+disease+2019+%28COVID-19%29%22">Coronavirus disease 2019 (COVID-19)</searchLink><br /><searchLink fieldCode="DE" term="%22Chemistry%22">Chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Cathepsin+L+activity%22">Cathepsin L activity</searchLink><br /><searchLink fieldCode="DE" term="%22viruses%22">viruses</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22HIV+Protease+Inhibitor%22">HIV Protease Inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Saquinavir%22">Saquinavir</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The 2019 coronavirus disease pandemic (COVID-19) has mobilized efforts worldwide, and several ongoing clinical trials aimed at developing a drug-based treatment for its control. Cathepsin L is an endosomal cysteine protease that mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells and viruses/host cell endosome membrane fusion. Therefore, cathepsin L is a potential target for the treatment of COVID-19 patients. In this report, we describe a previously unknown inhibitory effect of two FDA-approved drugs, saquinavir and nelfinavir, on human cathepsin L activity. Whether the pivotal role for cathepsin L in Sars-Cov-2 infection described in vitro can be translated to humans, our results support immediate clinical trials of saquinavir or nelfinavir as a potential treatment for COVID-19 patients. ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_________::977c35bda94d332867bad62843db88a7" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_________::977c35bda94d332867bad62843db88a7</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.21203/rs.3.rs-37258/v1" linkWindow="_blank">https://doi.org/10.21203/rs.3.rs-37258/v1</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi...........977c35bda94d332867bad62843db88a7 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Nelfinavir
[Type] => general
)
[1] => Array
(
[SubjectFull] => Coronavirus disease 2019 (COVID-19)
[Type] => general
)
[2] => Array
(
[SubjectFull] => Chemistry
[Type] => general
)
[3] => Array
(
[SubjectFull] => Cathepsin L activity
[Type] => general
)
[4] => Array
(
[SubjectFull] => viruses
[Type] => general
)
[5] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[6] => Array
(
[SubjectFull] => HIV Protease Inhibitor
[Type] => general
)
[7] => Array
(
[SubjectFull] => Pharmacology
[Type] => general
)
[8] => Array
(
[SubjectFull] => Saquinavir
[Type] => general
)
[9] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => HIV protease inhibitors saquinavir and nelfinavir are potent inhibitors of cathepsin L activity: A potential treatment for COVID-19 patients
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yousef Al-Abed
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kevin J. Tracey
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mingzhu He
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Timothy R. Billiar
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marcelo F. Montenegro
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 22
[M] => 06
[Type] => published
[Y] => 2020
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
)
)
)
)
)
|
| IllustrationInfo |